[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-aspergillosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-aspergillosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390",false,"NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","ALL","18 Years","90 Years",{"count":20,"type":21},400,"ESTIMATED","30 Days","OBSERVATIONAL","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[26,27,28,29,30,31,32,33,34,35],"Pneumonia","Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[27,37,29,38,32,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","RECRUITING","2026-06-26",{"date":57,"type":58},"2026-07-02","ACTUAL",{"date":60,"type":58},"2025-11-13",{"date":62,"type":21},"2031-11-13",{"name":64,"class":65},"Azienda Ospedaliero-Universitaria Careggi","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":66},"100534911","phase-2-imaging-pulmonary-aspergillosis-using-gallium-68-deferoxamine-100534911","NCT06244979","iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine","MIRAGE","Inclusion Criteria:\n\n1. The patient is at least 18 years old on the day of inclusion.\n2. The patient has suspected chronic pulmonary aspergillosis or ABPA.\n3. There is no significant interference with standard care and follow-up.\n\nExclusion Criteria:\n\n1. The patient is pregnant or planning on becoming pregnant.\n2. The patient has severe kidney dysfunction with eGFR \\\u003C 30 ml\u002Fmin\u002Fkg and\u002For receives dialysis.\n3. The patient has (chronic) iron overload.\n4. The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.\n5. The patient is not able to lie still in the scanner.",{"count":75,"type":21},10,"INTERVENTIONAL",[78],"PHASE2","This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of \\[68Ga\\]Ga-DFO-B PET\u002FCT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection.\n\nThe incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like \\[68Ga\\]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, \\[68Ga\\]Ga-DFO-B PET\u002FCT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.",[29,81,82],"Chronic Pulmonary Aspergillosis","Allergic Bronchopulmonary Aspergillosis","2025-05-19",{"date":85,"type":58},"2025-05-22",{"date":87,"type":58},"2025-05-01",{"date":89,"type":21},"2026-05-01",{"name":91,"class":65},"Radboud University Medical Center"]